CTD HOLDINGS INC Form 10QSB May 15, 2008

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549

FORM 10-QSB

$_X$ Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 for the quarterly period ended: March 31, 2008.
Transition Report Under Section 13 or 15(d) of the Exchange Act for the
transition period from to
Commission file number: 0-24930
CTD HOLDINGS, INC.
(Exact name of small business issuer as specified in its charter)

59-3029743

(IRS Employer Identification No.)

27317 N.W. 78th Avenue, High Springs, Florida 32643 (Address of principal executive offices) (Zip Code)

Issuer's telephone number, including area code: 386-454-0887

Former name, former address and former fiscal year, if changed since last report: N/A.

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. (x)Yes (\_) No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) (\_)Yes (x)No

As of May 12, 2008, the Company had outstanding 20,930,764 shares of its common stock.

Transitional Small Business Disclosure Format: (\_) Yes (x) No

PART I. Financial Information

Item 1. Financial Statements.

Florida

(State or other jurisdiction of incorporation or organization)

CTD HOLDINGS, INC.
CONSOLIDATED BALANCE SHEET
(Unaudited)

ASSETS

March 31,2008
----\$ 295,801

CURRENT ASSETS

Cash and cash equivalents

Certificate of deposit Accounts receivable Inventory Deferred tax asset Investment due from related party Other current assets	52,027 32,614 100,812 75,000 788 2,000
Total current assets	559,042
PROPERTY AND EQUIPMENT, NET	451,041
OTHER ASSETS Intangibles, net	61,683
Deferred tax asset	390 <b>,</b> 000
Total other assets	451 <b>,</b> 683
TOTAL ASSETS	\$ 1,461,766 =======

(Continued)

F-1

# CTD HOLDINGS, INC. CONSOLIDATED BALANCE SHEET (Unaudited)

#### LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES  Accounts payable and accrued expenses \$ 92,532  LONG-TERM LIABILITIES
Loan from officer 25,856
STOCKHOLDERS' EQUITY Common stock, par value \$ .0001 per share, 100,000,000 shares authorized, 22,574,290 shares issued and outstanding 2,257
Preferred stock, par value \$.0001  per share, 5,000,000 shares authorized; Series A, 1 share issued and outstanding  Additional paid-in capital Accumulated deficit  3,077,576
Total stockholders' equity 1,343,378
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY \$ 1,461,766

See Accompanying Notes to Financial Statements.

F-2

# CTD HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

		Three Months Ended March 31,		
		2008		2007
PRODUCT SALES	\$	68,470	\$	151 <b>,</b> 226
COST OF PRODUCTS SOLD		20,541		2,145
GROSS PROFIT		47 <b>,</b> 929		149,081
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES Selling, general and administrative Legal		128 <b>,</b> 119 6 <b>,</b> 415		
Total selling, general and administrative expenses		134,534		150,931
OTHER INCOME (EXPENSE) Investment and other income Interest expense		6,033 (1,716)		6,942 (1,779)
Total other income (expense)		4,317		5 <b>,</b> 163
NET INCOME (LOSS) BEFORE INCOME TAXES		(82,288)		3,313
INCOME TAX BENEFIT		15,000		-
NET INCOME (LOSS)	\$	(67,288)	\$	3,313
NET INCOME (LOSS) PER COMMON SHARE Net income (loss) per share	\$	(.003)	\$	(.000)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	21	L,699,291	16	5,077,937

See Accompanying Notes to Financial Statements

F-3

CTD HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Increase (Decrease) in Cash and Cash Equivalents

(Unaudited)

CARL BLONG FROM ODERATING ACTIVITIES		
CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss)	\$ (67,288)	\$ 3,313
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization Stock compensation to employees Income tax benefit of deferred tax assets Increase or decrease in:	7,603 47,013 (15,000)	
Accounts receivable Inventory Other current assets	52,820 6,812 442	(13,826)
Accounts payable and accrued expenses		(7 <b>,</b> 867)
Total adjustments	118,558	8,728
NET CASH PROVIDED BY OPERATING ACTIVITIES	51,270	12,041
CASH FLOWS FROM INVESTING ACTIVITIES  Purchase of equipment and building improvements  Patent database development  Investment with related party  Redemption of certificate of deposit	(18,905) (23,020) 65 211,958	(6,976) - (6,449)
NET CASH PROVIDED BY (USED FOR) INVESTING ACTIVITIES	170,098	(13, 425)
CASH FLOWS FROM FINANCING ACTIVITIES Payments on notes payable Payments on received stockholder loan	(140,074) 4,526	(1,129) 18,113
NET CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES	(135, 548)	16,984
NET INCREASE IN CASH AND CASH EQUIVALENTS	85 <b>,</b> 820	15,600
CASH AND CASH EQUIVALENTS, beginning of period	209,981	23,629
CASH AND CASH EQUIVALENTS, end of period	\$ 295,801	
	========	

# CTD HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Increase (Decrease) in Cash and Cash Equivalents (Unaudited) (Concluded)

(Concluded)				
	Three Months Ended March 31,			
	2008		2007	
SUPPLEMENTAL DISCLOSURE OF CASH FLOW Cash paid for interest	\$	1,716 	\$	1,779 
Cash paid for income taxes	\$	_	\$	_
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING				

AND FINANCING ACTIVITIES

Common stock awarded to officers

See Accompanying Notes to Financial Statements

F-5

CTD HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2008

(Unaudited)

The information presented herein as of March 31, 2008 and for the three months ended March 31, 2008 and 2007, is unaudited.

#### (1) BASIS OF PRESENTATION:

The accompanying financial statements include CTD Holdings, Inc. and its subsidiaries.

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Rule 10-01 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

Operating results for the three month period ended March 31, 2008, are not necessarily indicative of the results that may be expected for the year ending December 31, 2008. For further information, refer to the financial statements and footnotes thereto included in the Company's annual report of Form 10-KSB for the year ended December 31, 2007.

#### (2) NET INCOME (LOSS) PER COMMON SHARE:

Net income (loss) per common share is computed in accordance with the requirements of Statement of Financial Accounting Standards No. 128 (SFAS 128). SFAS 128 requires net income (loss) per share information to be computed using a simple weighted average of common shares outstanding during the periods presented. SFAS 128 eliminated the previous requirement that earnings per share include the effect of any dilutive common stock equivalents in the calculation.

#### (3) INCOME TAXES

For 2008, the Company reported a net loss and also realized a net operating tax loss for the three months ended March 31, 2008. The Company recorded the future benefit of this tax loss as a deferred tax asset and an income tax benefit of \$15,000 based on management's expectation that it is more likely than not the Company will report net income and net taxable income for 2008 and future years sufficient to utilize its net operating loss carryforwards.

For 2007, no income tax expense was reported for the three month period ended March 31, 2007, due to the Company utilizing the benefit of its net operating loss carryforward. In the fourth quarter of 2007, we reduced the valuation allowance on our deferred tax asset by \$450,000.

#### (4) CONCENTRATIONS

Sales to one major customer was 26% of total sales for the three months ended March 31, 2008. Sales to the three major customers were 64% of total sales for the three months ended March 31, 2007.

Substantially all 2007 and 2006 inventory purchases were from three vendors.

The Company has only one source for certain manufactured inventory. However, the Company has manufactured these products in the past and could do so again, if necessary. There are multiple sources for its other inventory products.

F-7

#### (5) COMMITMENTS AND CONTINGENCIES

For 2008, the Company has employment agreements with two officers for total monthly salaries of \$10,000. In addition, the officers are awarded shares of common stock each month. The number of shares due is equal to \$13,500 divided by eighty percent of the closing price of the Company's common stock on that last day of each month. The Company recognizes an expense equal to the fair value of the stock determined using the average stock closing trading price for the month multiplied by the number of shares awarded for that month. The stock is subject to trading restrictions under Rule 144. Also, the Company issued shares to one of its employees. The number of shares due is equal to \$500 divided by eighty percent of the closing price of the Company's common stock on the last day of each month. For the three months ended March 31, 2008, the Company awarded 1,749,999 shares and recognized an expense of \$47,013 for stock awarded under these agreements.

For 2007, the Company has employment agreements with two officers for total monthly salaries of \$5,000. In addition, the Company's president is awarded shares of common stock each month. The number of shares due is equal to \$6,500 divided by eighty percent of the closing price of the Company's common stock price on the last day of each month. The Company recognizes an expense equal to the fair value of the stock determined using the average stock closing trading price for the month multiplied by number of shares awarded for that month. The stock is subject to trading restrictions under Rule 144. For the three months ended March 31, 2007, the Company awarded 744,792 shares and recognized an expense of \$25,052 for stock awarded under the agreements.

On February 7, 2007, Registrant and C.E. Rick Strattan filed suit in Circuit Court in Palm Beach County, Florida, (Case Number 2007CA001818XXXXMB) seeking the return of the Class A Preferred Share and damages from defendants Eline Entertainment Group, Inc., Eline Holding Group, Inc., Yucatan Holding Company, Steven T. Dorrough, Jayme Dorrough, and Barry Rothman, based on representations made in connection with the Share Exchange Agreement dated August 11, 2005, as amended and the enforcement of the agreement.

#### (6) CHANGE IN ACCOUNTING ESTIMATE

During 2007, the Company received a favorable price adjustment for inventory acquired and resold in 2006, resulting in reduction in cost of goods sold for 2007 of \$7,700 in the quarter ended March 31, 2007.

Item 2. Management's Discussion and Analysis or Plan of Operation.

Introduction

CTD Holdings, Inc. (referred to as the "Company," "CTD" or in the first person notations of "we," "us," and "our") began operations in 1990. Our revenues are principally derived from retail sales of cyclodextrins and cyclodextrin complexes. Our sales are primarily to major chemical supply houses around the world, pharmaceutical companies, and food companies for research and development and to diagnostics companies. We acquire many of our products outside the United States, from Japan, Germany, China and Hungary; but we are gradually finding satisfactory supply sources in the United States. While we generally enjoy better supply prices from outside the United States, rising shipping costs are making domestic sources more competitively priced. To add value to our products, we maintain a comprehensive database of patented and patent pending uses of cyclodextrins from the United States Patent Trademark Office. We also maintain a less comprehensive database that includes patents issued in many other countries including Japan, Germany and others. This information is available to our customers. We also offer our customers our knowledge of the properties and potential new uses of cyclodextrins and cyclodextrin complexes.

As most of our customers use our cyclodextrin products in their research and development activities, their ordering from us is unpredictable with regard to timing, product mix and volume. We also have four major customers who have a significant effect on our revenues when they increase or decrease their research and development activities that use cyclodextrins. We keep in constant contact with these customers as to their cyclodextrin needs so we can maintain the proper inventory composition and quantity in anticipation of their needs. The sales to major customers and the product mix and volume of products sold has a significant effect on our revenues and gross profit. These factors contribute to our significant revenue volatility from quarter to quarter and year to year.

We are engaged in litigation with Eline Entertainment Group, Inc. (Eline) over breech of contract and the return of a stock power authorization of our one share of Series A Preferred Stock.

In 2004, we amended the Company's Articles of Incorporation authorizing a series of "blank check" preferred stock consisting of 5,000,000 shares and creating a series of Series A Preferred Stock, setting forth its designations, rights and preferences. The more significant right is Series A Preferred shareholders vote with the holders of common stock on all matters submitted to a vote of our shareholders. Shares of Series A Preferred Stock are entitled to one vote more than one-half of all votes entitled to be cast by all holders of voting capital stock of the Company on any matter submitted to holders of common shares so as to ensure that the votes entitled to be cast by the holder of the Series A Preferred Stock are equal to at least a majority of the total of all votes entitled to be cast by the holders of common shares. In 2004, we issued one share of Series A Preferred Stock to C.E. Strattan, our majority shareholder in exchange for 1,029,412 shares of common stock held by him, which he voluntarily surrendered to the Company and were cancelled. Effective August 11, 2005, C.E. Strattan contractually transferred the one outstanding share of Series A Preferred Stock to Eline Entertainment Group, Inc. (Eline). The agreement with Eline provides for advances to the Company of up to an aggregate of \$1,500,000 to acquire Cyclolab, at Eline's sole discretion. Eline is an SEC reporting company currently not in reporting compliance. In September 2006, the Company's President, Mr. Strattan, demanded, in accordance with the expired contract, the return of the Series A Preferred Stock in the form of a stock power authorization since the physical share never left the possession of its original owner, Mr. Strattan. The demand letter was sent to the address given in the contract and was never acknowledged nor responded to by Eline. The Company has filed a legal action with regard to its agreement with Eline. See "Legal Proceedings".

The Company's Board of Directors has decided to create an additional class of preferred share to be referred to as the Series B Preferred Share. The Series B Preferred Share would entitle the holder to vote, in addition to other shares owned by the holder, the number of votes equal to the number of the authorized, but unissued common shares of the Company. Action to approve the proposed amendment would not occur until an Information Statement is filed and approved by the Securities and Exchange Commission.

#### Liquidity and Capital Resources

Our cash and short-term investments and certificates of deposit decreased to \$348,000 as of March 31, 2008, compared to \$474,000 as of December 31, 2007. The decrease for the three months ended March 31, 2008, was due primarily to positive cash flow from operations less the \$140,000 payoff of the mortgage on our property.

As of March 31, 2008, our working capital was \$467,000 compared to \$504,000 at December 31, 2007. Our cash flows from operations for the first three months of 2008 was \$51,000 compared to \$12,000 for the same period in 2007. This increase was due primarily to timing differences in accounts receivable and accounts payable.

We accumulated almost \$500,000 in cash in January 2008, which is in excess of our requirements for normal operations and capital projects. We determined the best use of our additional cash was to pay off the \$140,000 mortgage on our property, which we did in February 2007. This reduces interest expense \$850 per month.

We believe our remaining working capital is sufficient to run our operations at current expected future operating levels into the near future. We do not require capital in the next twelve months for normal operations.

In April 2008, we ordered \$80,000 of one inventory product (TRMB) in anticipation of a large order from one of our major customers later in 2008. This product has a three month or more lead time to acquire from the manufacturer in the quantity purchased. If this large order does not materialize, we can sell this product in the normal course of business.

Controlling cash expenses continues to be management's primary fiscal tool. However, growth requires increased expenditures and we feel that it is appropriate during the current growth stage to engage consultants that can help the Company in financial areas outside its expertise, accepting that these fees will act to reduce profitability. We are working hard to increase revenues to balance these new expenses, but cannot be sure that such effort will be enough in the short term to sustain profitable financial performance.

Beginning in 2003, we began improvements and renovations of our corporate office and have invested \$191,000 through December 31, 2007, including paving our limerock driveway and completing our office renovation. During the three months ended March 31, 2008, we capitalized \$19,000 of improvements including paving the first 300 feet of our driveway. Currently we are conducting an extensive survey of our 40 acres of property and existing facilities in preparation for developing a total site plan for our Research Park facility. In 2008, we plan to renovate three existing structures to be an inventory warehouse and an educational auditorium at a estimated cost of \$60,000. These buildings have been previously idle. Over the next five years, we plan to renovate or construct at least six buildings for an estimated cost of \$150,000.

Currently, we are developing a site plan for the research park including survey, engineering and design. The progress of the site plan is contingent on the Company's ability to fund our building plan from operating profits and cash flow. At the conclusion of the site plan, we plan to sell additional stock to finance the building construction of the research park.

During 2007, we began a major upgrade and update of our searchable cyclodextrin patent database. This database will be an important resource for our customers seeking information on existing U.S. patented applications of cyclodextrins. We have capitalized \$56,000 for this database through March 31, 2008. We expect the initial project to cost \$85,000 and to be completed by December 31, 2008. We plan to begin selling subscriptions to customers. During the first quarter of 2008, we expanded the project to include significant data verification and increased the budget by \$30,000. We plan to implement phase II after revenue has been generated from Phase I. Phase II will include entering U.S. patent applications into the database. Throughout, we will continue to enhance the database for ease of use and completeness. We have not budgeted Phase II at this time. We expect annual database enhancement and maintenance costs to be at least \$20,000 annually for the foreseeable future.

We issued 1,749,999 shares and 744,792 shares of our common stock to officers and employees for compensation earned under employment agreements for 2008 and 2007, respectively.

We have no off-balance sheet arrangements at March 31, 2008.

Results of Operations

Total product sales for the three months ended March 31, 2008 were \$68,000 compared to \$151,000 for the same period in 2007. Our major customers continue to be repeat purchasers. In 2008, we had one major customer account for 26% of our sales. In 2007, we had three major customers accounting for 64% of our sales. The decrease in sales was due primarily to less sales to our major customers.

Our gross profit margin decreased to 70% for the three months ended March 31, 2008 from 99% for the three months ended March 31, 2007, compared to 85% for the year ended December 31, 2007. This decrease is part of our normal volatility of sales volume and mix of products. During 2007, we received a favorable price adjustment for some inventory we acquired and resold in 2006, resulting in reduction in our 2007 cost of goods sold of \$7,700, which had a 5% favorable gross profit effect. Changes in the product mix in sales also has a significant effect on our overall gross profit percentage from period to period.

The decrease in the value of the U.S. dollar in relation to the Euro and other foreign currencies has affected our cost of inventory, and will continue to do so. We buy most of our products from outside the U.S. Our main supplier of fine chemicals and complexes has raised its prices 10-15% in Euros. This increase combined with the decline in the U.S dollar, has seen our costs for these products increase 55-65%. The cost of our bulk inventory has also increased due to the decline of the U.S. dollar. These products represent a significant portion of our revenues. We are not able to raise our prices sufficient to maintain our historical gross profit percentage and therefore, expect our gross profit percentage to decline in future quarters.

Our SG&A expenses decreased to \$135,000 for the three months ended March 31, 2008, from \$150,000 for the three months ended March 31, 2007. During 2008, our stock compensation expense increased to \$47,000 from \$25,000 in 2007. During

2007, SG&A expenses include a \$25,000 cash bonus to our President and \$18,000 in legal expenses related to the lawsuit with Eline Entertainment Group, Inc.

We may incur significant future legal fees as the result of our lawsuit with Eline Entertainment Group, Inc.

We recognized a net loss of (67,000) for the three months March 31, 2008, compared to net income of 3,000 for the three months ended March 31, 2007.

We will continue to introduce new products that will increase sales revenue and implement a strategy of creating or acquiring operational affiliates and/or subsidiaries that will use cyclodextrins in herbal medicines, waste-water remediation, pharmaceuticals, and foods. We also intend to pursue exclusive relationships with major cyclodextrin manufacturer(s) and specialty cyclodextrin labs to distribute their products. We continue to be the exclusive distributor in North America of the cyclodextrin products manufactured by Cyclolab Research Laboratories in Budapest, Hungary.

In keeping with its commitment to use the internet as a major advertising and public relations outlet, the Company intends to apply greater human resources to the updating and maintaining of its web site. This valuable asset has been instrumental in creating and maintaining a worldwide leadership role for us in the implementation of research and commercialization of CD applications. We believe the maintenance and growth of our web site will return that investment many times.

#### Item 3. Controls and Procedures.

#### (a) Evaluation of disclosure controls and procedures.

The Company's management and Chief Executive Officer and Chief Financial Officer, recognize their responsibility for establishing and maintaining internal control over financial reporting for the Company. After evaluating the effectiveness of our "disclosure controls and procedures" (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of March 31, 2006 (the "Evaluation Date"), the Company's management has concluded, as of the Evaluation Date and the quarter ended March 31, 2008, the Company's disclosure controls and procedures were adequate and designed to ensure the information required to be disclosed in the reports filed or submitted by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported with in the requisite time periods. Although management and the Chief Executive Officer and Chief Financial Officer believe existing disclosure controls and procedures are adequate, the Company's management and the Chief Executive Officer and Chief Financial Officer acknowledge a material weakness may exist in those controls and procedures in that i) the accountant employed by the Company has no training regarding financial reporting and presentation rules and regulations of the SEC; and ii) the Company's President/CEO, who oversees all the accountants' work and provides all internal control functions, while possessing a MBA from the University of Florida, has no training in matters of accounting, financial reporting, or presentation rules and regulations of the SEC.

#### (b) Effectiveness of Internal Control

The Company's management is reviewing the Company's internal controls over financial reporting to determine the most suitable recognized control framework. The Company will give great weight and deference to the product of the discussions of the SEC's Advisory Committee on Smaller Public Companies (the "Advisory Committee") and the Committee of Sponsoring Organizations' task force entitled Implementing the COSO Control Framework in Smaller Businesses (the

"Task Force"). Both the Advisory Committee and the Task Force are expected to provide practical, needed guidance regarding the applicability of Section 404 of the Sarbanes-Oxley Act to small business issuers. The Company's management intends to perform the evaluation required by Section 404 of the Sarbanes-Oxley Act at such time as a framework is adopted by the Company. For the same reason, the Company's registered accounting firm has not issued an "attestation report" on the Company management's assessment of internal controls. Although the Company's existing disclosure controls and procedures are adequate, the Company's management acknowledges a material weakness may exist in those controls and procedures in that i) the accountant employed by the Company has no training regarding financial reporting and presentation rules and regulations of the SEC; and ii) the Company's President/CEO, who oversees all the accountants' work and provides all internal control functions, while possessing a MBA from the University of Florida, has no training in matters of accounting, financial reporting, or presentation rules and regulations of the SEC.

(c) Changes in internal controls.

After evaluation by the Company's management, the Company's management has determined there were no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's internal controls subsequent to the Evaluation Date.

Part II. OTHER INFORMATION

Item 1. Legal Proceedings.

NONE

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

NONE

Item 3. Defaults Upon Senior Securities.

NONE

Item 4. Submission of Matters to a Vote of Security Holders.

NONE

Item 5. Other Information.

The Company's Board of Directors has decided to create an additional class of preferred share to be referred to as the Series B Preferred Share. The Series B Preferred Share would entitle the holder to vote, in addition to other shares owned by the holder, the number of votes equal to the number of the authorized, but unissued common shares of the Company. Action to approve the proposed amendment would not occur until an Information Statement is filed and approved by the Securities and Exchange Commission.

Item 6. Exhibits.

(2) Plan of purchase, sale, reorganization, arrangement, liquidation or succession

None

(3) Articles of Incorporation and By-Laws

	(i)	Articles of Incorporation filed August 9, 1990	7
	(ii)	By-Laws	7
	(iii)	Certificates of Amendment to the Articles of Incorporation filed November 18, 1993 and September 24, 1993	,
(4)		uments defining the rights of security holders, ding indentures	,
	(a) S	Specimen Share Certificate for Common Stock.	3
(10)	Materi	al contracts	
	(10.1)	Agreement of Shareholders dated November 11, 1993 by and among C.E. Rick Strattan, Garrison Enterprison. and the Company.	ses,
	(10.2)	Lease Agreement dated July 7, 1994.	* :
	(10.3)	Consulting Agreement dated July 29, 1994 between the Company and Yellen Associates.	5
	(10.4)	License Agreement dated December 20, 1994 between the Company and Herbe Wirkstoffe GmbH.	1
	(10.5)	Joint Venture Agreement between the Company and Ocumed, Inc. dated May 1, 1995, incorporated by reference to the Company's Form 10-QSB for the quarter ended June 30, 1995.	*:
	(10.6)	Extension of Agreement between the Company and Herbe Wirkstoffe GmbH.	**;
	(10.7)	Lease Extension	-
	(10.8)	Loan Agreement with John Lindsay	-
	(10.9)	Small Potatoes Contract	-
	(10.10)	Employment Agreement with C.E. Rick Strattan dated May 30, 2001	+-
	(10.11)	Employment Agreement of C.E. Rick Strattan dated October 14, 2003	++-
	(10.12)	Employment Agreement of George L. Fails dated October 14, 2003	***
	(10.13)	Addendum to Share Exchange Agreement with Eline Entertainment Group	+++-
	(10.14)	Share Exchange Agreement with Eline Entertainment Groups	++++
(11)	State	ment re: computation of per share earnings	Note 2 to Financial Statements

(15)	Letter on unaudited interim financial information	****
(18)	Letter on change in accounting principles	None
(19)	Reports furnished to security holders	None
(20)	Other documents or statements to security holders or any document incorporated by reference	None
(22)	Published report regarding matters submitted to vote of security holders	None
(23)	Consents of experts and counsel	None
(24)	Power of Attorney	None
(31)	Rule 13a-14(a)/15d-14a(a) Certifications	****
(32)	Section 1350 Certifications	***
(99)	Additional exhibits	None
(100	)XBRL-Related Documents	None

- \* Incorporated by reference to the Company's Form 10-SB filed with the Securities and Exchange Commission on February 1, 1994.
- \*\* Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on March 29, 1997.
- \*\*\* Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on March 28, 2000.
- \*\*\*\* Filed herewith.
- + Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on April 2, 2001.
- ++ Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on April 1, 2002.
- +++ Incorporated by reference to Form S-8 filed December 1, 2003.
- ++++ Incorporated by reference to the Company's Form 8-K filed with the Securities and Exchange Commission on September 21, 2005.
- +++++Incorporated by reference to the Company's Form 8-K filed with the Securities and Exchange Commission on August 15, 2005.

#### SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CTD HOLDINGS, INC.

Date: May 15, 2008 /s/ C.E. Rick Strattan

-----

C.E. Rick Strattan Chief Executive Officer Chief Financial Officer